Cargando…

Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Detalles Bibliográficos
Autores principales:	Ghosh, Subrata, Gensler, Lianne S., Yang, Zijiang, Gasink, Chris, Chakravarty, Soumya D., Farahi, Kamyar, Ramachandran, Paraneedharan, Ott, Elyssa, Strober, Bruce E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520476/ https://www.ncbi.nlm.nih.gov/pubmed/31012051 http://dx.doi.org/10.1007/s40264-019-00816-3

Ejemplares similares

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015)

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis
por: Abraham, Bincy P, et al.
Publicado: (2022)

Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019)

Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
por: Sandborn, William J, et al.
Publicado: (2020)

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
por: Matsumoto, Satohiro, et al.
Publicado: (2018)

Ustekinumab for the treatment of psoriatic arthritis: an update
por: Davari, Parastoo, et al.
Publicado: (2014)

Pustular Rash in Crohn's Patient on Ustekinumab Raises Concern for Drug-Induced Paradoxical Psoriasis
por: Barahimi, Mitra, et al.
Publicado: (2021)

Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study
por: Tillett, William, et al.
Publicado: (2023)

Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)

Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study
por: Gossec, Laure, et al.
Publicado: (2023)

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
por: Hibi, Toshifumi, et al.
Publicado: (2017)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Thyrotoxicosis Associated with Ustekinumab Treatment for Psoriasis
por: Olabi, Bayanne, et al.
Publicado: (2020)

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2
por: McInnes, Iain B, et al.
Publicado: (2019)

Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report
por: Babalola, Olubukola, et al.
Publicado: (2014)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
por: Montepaone, Monica, et al.
Publicado: (2014)

Paradoxical Flare of Psoriasis after Ustekinumab Therapy
por: Lee, Ho Yeol, et al.
Publicado: (2017)

Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis
por: Lynch, Maeve, et al.
Publicado: (2017)

Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016)

Metastatic Vulval Crohn’s Disease With Good Outcome on Ustekinumab
por: Lim, Yizhe, et al.
Publicado: (2021)

Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis
por: Gediz, Fusun, et al.
Publicado: (2021)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Emerging treatments in the management of psoriasis: biological targeting with ustekinumab
por: Papoutsaki, Marina, et al.
Publicado: (2009)

Recalcitrant psoriasis responding to new bilogic drug: Ustekinumab
por: Husein-ElAhmed, Husein, et al.
Publicado: (2013)

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis
por: Tsakok, Teresa, et al.
Publicado: (2019)

Genome-Wide Association Study of Ustekinumab Response in Psoriasis
por: Connell, William T., et al.
Publicado: (2022)

Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
por: Yang, Seungkeol, et al.
Publicado: (2021)

Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
por: Orbai, Ana-Maria, et al.
Publicado: (2023)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
por: Rahme, Elham, et al.
Publicado: (2019)

Successful Drug Desensitization to Ustekinumab in a Patient with Crohn's Disease
por: Cohen, Barrie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_610kivafknmhfna6v99kk36qbi